BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the second quarter of 2007. For the three months ended June 30, 2007, Enzon reported a net loss of $3.0 million or $0.07 per diluted share, as compared to net income of $11.0 million or $0.25 per diluted share for the same quarter in 2006. Second quarter results in 2006 were favorably impacted by the $3.1 million gain or $0.07 per share from the purchase of 4.5 percent convertible notes at a discount to par.
